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This is a case report of a 68-year-old man with hepatocellular carcinoma (HCC) accompanied by hereditary hemorrhagic 
telangiectasia (HHT), also known as Osler-Weber-Rendu disease, and hepatic vascular malformation. HHT is an 
autosomal dominant disorder of the fibrovascular tissue that is characterized by recurrent epistaxis, mucocutaneous 
telangiectasias, and visceral arteriovenous malformations. HHT is caused by mutation of the genes involved in the 
signaling pathway of transforming growth factor-β, which plays an important role in the formation of vascular endothelia. 
Hepatic involvement has been reported as occurring in 30-73% of patients with HHT. However, symptomatic liver 
involvement is quite rare, and the representative clinical presentations of HHT in hepatic involvement are high-output heart 
failure, portal hypertension, nodular regenerative hyperplasia, and symptoms of biliary ischemia. Some cases of HCC in 
association with HHT have been reported, but are very rare. We present herein the characteristic radiologic and genetic 
findings of HHT that was diagnosed during the evaluation and treatment of HCC. (Korean J Hepatol 2011;17:313-318)
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INTRODUCTION
Hereditary hemorrhagic telangiectasia (HHT), also known 
as Osler-Weber-Rendu disease, is an autosomal dominant 
multiorgan disorder caused by a genetic defect encoding a 
protein that binds transforming growth factor, which results 
in abnormal vascular remodeling in the form of fibrovascular 
dysplasia with multiple telangiectasias.
1 HHT is caused by 
mutations in one of two genes that have led to its subclassi-
fication into type 1 or 2 disease in most cases. HHT type 1 
disease, the disease-causing gene is located on chromosome 
9, encoding endoglin (ENG).
2 In HHT type 2, the disease- 
causing gene is located on chromosome 12, encoding 
activin receptor-like kinase 1 (ACVRL1).
3  HHT is characterized 
by the classic triad of mucocutaneous telangiectasias, 
recurrent epistaxis, and familial occurrence.
4 Multiple 
telangiectases consisting of thin-walled, dilated vascular 
channels with arteriovenous malformations may involve 
mucocutaneous tissue, gastrointestinal tract including the 
liver, lung, and brain.
5 The condition usually manifests in 
adults with epistaxis, hemoptysis, or both, and hepatic 
involvement is typically diagnosed 10-20 years after the first 
telangiectasias appear.
6,7 The diagnosis of HHT is 
established when any three of the following criteria are 
present: (1) spontaneous and recurrent epistaxis; (2) 
multiple telangiectasias at characteristic sites, including 
lips, oral cavity, fingers, and nose; (3) presence of internal 
lesions such as gastrointestinal telangiectasia, pulmonary, 314  The Korean Journal of Hepatology Vol. 17. No. 4, December 2011
   
Figure 1. Typical splinter-like telangiectasias on the patient’s arm (A), trunk (B), and midbody of the stomach (C). 
hepatic, cerebral, and spinal arteriovenous malformations 
(AVMs); and (4) family history in the first-digree relative.
8
Although the genotypic-phenotypic correlations are not 
yet fully defined, disease severity is more pronounced in 
HHT type 1 than in HHT type 2 with earlier age of onset for 
epistaxis and hepatic involvement were observed predominantly 
in HHT type 2.
9 We present here a case of HHT type 2 with 
hepatic involvement with hepatocellular carcinoma (HCC) 
and confirmed by the mutation in the ACVRL1. Transarterial 
chemoembolization (TACE) for the unresectable HCC was 
not effective in this case and even risky procedure when 
HCC is associated with HHT. 
CASE REPORT
A 68-year-old man was referred for evaluation of a 
hepatic mass. He had history of hepatitis B virus carrier for 
20 years and liver cirrhosis for 3 years. He has been taking 
an angiotensin receptor blocker and digoxin due to hypertension 
and heart failure. He has suffered from repeated episodes of 
epistaxis from his teens and gastrointestinal bleeding from 
his mid-thirties. All of his five children also had the history 
of recurrent epistaxis. Also his sister was suffering from the 
sequelae of cerebrovascular accident. On physical examination, 
several telangiectatic macular lesions were found on his 
arms and trunk (Fig. 1A, 1B). The laboratory work-up at first 
visit revealed the following: WBC, 4.6×10³/mm³; platelet, 
172×10³/mm³; hemoglobin, 12.6 g/dL; aspartate aminotran-
sferase (AST), 42 IU/L; alanine aminotranferase (ALT), 20 
IU/L; hepatitis B virus surface antigen, positive; hepatitis B 
surface antibody, negative; anti-hepatitis C virus antibody, 
negative; and alpha-fetoprotein (AFP), 345 ng/mL (normal, 
0-20). Other laboratory results including bleeding time, 
coagulation time, prothrombin time and activated partial 
thromboplastin time were normal. Gastroduodenal endoscopy 
disclosed a telangiectasia at the lesser curvature in mid-body 
of the stomach (Fig. 1C). Liver dynamic CT (LDCT) revealed 
multiple HCCs in the right lobe of liver and there was no 
evidence of distant metastasis or vascular invasion. The 
HCC lesions showed heterogenous wash-out compared to 
well enhancing round homogenous AVMs in delayed phase 
of LDCT (Fig. 2). 
Liver transplantation was recommended, however, the 
patient refused it due to economic problem. TACE was 
performed in three consecutive sessions, but lipiodol uptake 
in the tumor mass was very poor at every session. HCC 
progressed after each TACE session. Fever developed up to 
38℃, and AST and/or ALT increased more than two times 
of baseline following the first two TACE sessions.
Because of unusual TACE effect, we reviewed all the 
radiologic images of the patient and found an enlarged 
tortuous hepatic artery, multiple arteriovenous malformations, 
and early visualization of hepatic veins in LDCT (Fig. 2) and 
hepatic angiography (Fig. 3). Based on these findings and 
positive family history, he was diagnosed as Osler-Weber- 
Rendu disease and genetic tests for the ENG and ACVRL1 
were performed. Patient’s genomic DNA was isolated from 
peripheral blood using the QuickGene DNA blood kit 
(Fujifilm, Tokyo, Japan) and BigDye Terminatore V3.1 
Cycle Sequencing Ready reaction kit (Applied Biosystems, 
Foster city, CA, USA). Fourteen and ten exons and their 
intronic flanking sequences of the ENG and ACVRL1, 
respectively, were amplified by polymerase chain reaction 
with appropriate primers (Table 1 and Fig. 4). The molecular 
genetic analysis for the whole exons with their flanking 
sequences of the ENG was negative. However, the patient 
harbors a deletion mutation, c.145del (p.Ala49ProfsX5), in 
the  ACVRL, the diagnosis of HHT type 2 with hepatic 
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Figure 2. Dynamic liver CT images of hereditary hemorrhagic telangiectasia (HHT) and hepatocellular carcinoma (HCC) in a 68-year-old 
man. (A) In the arterial phase, the CT angiogram showed diffuse parenchymal heterogeneous enhancement and numerous telangiectasias, 
mainly in hepatic segment IV (arrow), which is characteristic of HHT. (B) Delayed washout of HCC (arrow) was observed in hepatic 
segment VII. (C) Post-transarterial chemoembolization (TACE) CT image obtained in the arterial phase showing early filling of the 
mid-hepatic vein (thin arrow) with a hepatic artery to hepatic vein shunt (thick arrow). (D) The same CT image as in Fig. 2C showing 
left hepatic artery enlargement (thick arrow) and multiple vascular malformations (thin arrows).
involvement was confirmed by the results of genetic study. 
He is waiting for deceased donor liver transplantation for the 
treatment of HCC.
DISCUSSION
HHT or Osler-Weber-Rendu disease is a rare systemic 
fibrovascular dysplasia with autosomal dominant transmission, 
characterized by recurrent epistaxsis, mucocutaneous 
telangiectasis, and visceral AVMs.
1 It has an estimated 
prevalence of 1 in 5,000-10,000. Recurrent epistaxis is often 
the first and most common manifestation.
4 The dilated post 
capillary venule fuses with an arteriole bypassing the capillary 
system and resulting in an arterio-venous communication.
5
 HHT is caused by the mutation of the genes involved in 
the transforming growth factor-β signaling pathway which 
plays an important role in the formation of vascular endothelium.
8 
Two major types of HHT (HHT type 1 and type 2) are due to 
mutations of ENG and ACVRL, respectively. The ENG is 
located on the long arm of chromosome 9 (9q33-34) and 
determine the HHT type 1 disease, which correlates with a 
more critical pulmonary involvement and earlier age of 
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Figure 3. Hepatic arteriogram obtained during TACE. (A) Early hepatic arteriogram showing diffuse parenchymal heterogeneity with 
a mosaic pattern of perfusion characterized by multiple irregular telangiectatic vascular lesions (arrows). (B) Late hepatic arteriogram 
showing a dilated, tortuous hepatic artery (thick arrow) and early filling of the hepatic vein (thin arrow).
• Partial seq. of ACVRL1 gene.
Normal
Patient
c.145del (p.Ala49ProfsX5)
Figure 4. Molecular genetic analysis for the entire exons with 
their flanking sequences was negative for ENG. However, the 
patient harbored a deletion mutation, c.145del (p.Ala49ProfsX5), 
in  ACVRL1 (arrow).
onset for epistaxis.
10 The ACVRL1 located on the long arm 
of chromosome 12 (12q13) indicate the HHT type 2 disease, 
with a predominance of liver involvement.
2 Although the 
genotypic-phenotypic correlations are not yet fully defined, 
it appears that the liver involvement is more prevalent in 
HHT type 2. Our case also revealed to have the deletion 
mutation in the ACVRL, and the diagnosis of HHT type 2 
was made. He showed epistaxsis, mucocutaneous telangiec-
tasis and predominant hepatic AVMs with family history. 
Hepatic involvement occurs in 30% to 73% of patients 
with HHT.
11 However, most of them are asymptomatic. 
Symptomatic liver involvement is quite rare and symptoms 
occur in about 8% of the patients with HHT and liver 
vascular malformations.
3 Patients with hepatic involvement 
have hyperdynamic circulation resulting from arteriovenous 
shunting, portovenous shunting, or both, and may develop 
high-output cardiac failure. Other complications include 
extrahepatic shunts, portal hypertension, hepatic portosystemic 
encephalopathy, biliary ischemia, cholangitis, and liver 
failure.
6,7 The development of portal hypertension is mostly 
the result of shunting of blood from the hepatic artery to the 
portal vein. Perfusion abnormalities and tissue ischemia in 
the liver parenchyma can induce fibrosis around the 
abnormal vessels and hepatocellular regenerative activity. 
The combination of fibrotic telangiectases and nodular 
regenerative hyperplasia makes it hard to diagnose true 
hepatic mass lesions.
11
The LDCT can demonstrate an enlarged hepatic artery, 
arteriovenous shunt, and early draining hepatic vein in the 
liver.
12,13 Hepatic arteriography can be the best method of 
screening to characterize the liver vascular malformations.
The diagnosis of HCC is not easy in the background of the 
liver involved by HHT, because typical arterial enhancement 
and delayed washout pattern of HCC in dynamic CT scan 
could be masked by widespread AVMs and focal nodular 
hyperplasia common in HHT.
10 In our case, the diagnosis of 
HCC was possible due to typical radiologic features and Joo Ho Lee, et al. Osler-Weber-Rendu disease presenting with hepatocellular carcinoma  317
Table 1. Sequences of primers used in the polymerase chain reaction
Gene Sense (5’-to-3’) Antisense (5’-to-3’)
ENG Exon1 agaaggctggagcagggac gcataaccatttagttccagcaa
Exon2 tggctgtgatgatgcagga cactctcttggcaggggg
Exon3 gccagagggacaggcacta aggcaggaccctggtgaat
Exon4 attctcagctccggcctct gtggcatgtgaactgtggc
Exon5 gcaggtgagtggtggaagg gactggggtggggctttat
Exon6 ctatgggccccttccctt ctcctgctgcgtcttctgc
Exon7 ccgagctgagctgaaggac gcccaagctcacacagagg
Exon8 gagccaagatcgtgccact gcttgcagagggacgtgac
Exon9 aatgaagagggagcagggc gagactaagccaaccaatggc
Exon10 ggtggaggtgtgtttggga agagcgtcaccctcagcag
Exon11 tgagatcgcaccactgcac caggctgtctccctcctga
Exon12 tgtgaggactcaggggtgg cccttcctgcaaaccacag
Exon13 caggactcacccagaggca cccctgctctaggctgcta
Exon14 tgatgagcccgtttgctg cttgctgggggaacctgg
ACVRL1 Exon2 gaaccaggacttcccctgc ggggtagctggggactgag
Exon3 ggggtcagacgagagggac ccctttattggccagagca
Exon4 tgctctggccaataaaggg ctgggtcactgcaagctcc
Exon5 gggtgtaggaggggcagat agaacctagccctggccc
Exon6 cactgggtttgggtctgga ctgcaggtgggctgagagt
Exon7 cagtccattccctctcccc gctaatcatggtcaccgcc
Exon8 ctctgtggccactgccttc tgactgcaaacctcccagg
Exon9 tccctctcaggggtagcgt gccagggttgaaagaggga
Exon10 attaccggccatcctcctc gcccagctgtatttttggc
 ACVRL1, activin receptor-like kinase 1; ENG, endoglin.
elevated AFP level without liver biopsy.
HCC associated with HHT were rarely reported. Two 
cases reports have been published since 1975.
14,15 It has been 
suggested that development of HCC in HHT patients 
might be due to increased liver cell turnover resulted from 
‘over-nourishment’ of liver sinusoids by hepatic AVMs. So 
far, the causal relationship between HHT and HCC development 
is not clear.
TACE is one of effective treatment modalities especially 
in patients with unresectable HCC.
16 However, the presence 
of AVMs due to HHT could be an important barrier of 
effective TACE because blockade at feeding vessel in tumor 
is frequently impossible due to presence of AVMs. Usually 
the intrahepatic biliary tree obtains nearly all of its blood 
from the hepatic artery, so the presence of natural shunt from 
the hepatic artery to the hepatic or portal vein will result in 
biliary ischemia.
17 In this situation, the hepatic artery 
embolization might be a quite risky procedure.
3 In this case, 
three sessions of TACE were performed for the treatment of 
HCC, but those were ineffective and more severe deterioration 
of liver function was observed after TACE.
No treatment is recommended for HHT patients with 
asymptomatic liver involvement. In HHT patients with 
symptomatic liver disease, treatment can be divided into 
symptomatic treatment for the specific complications and 
management aimed at reducing the shunt by surgical ligation 
or transarterial embolization.
3 However, the hepatic artery 
embolization/ligation should be considered mainly in non- 
transplant candidate who failed maximal medical therapy 
due to the risk of necrotizing cholangitis and liver failure. 318  The Korean Journal of Hepatology Vol. 17. No. 4, December 2011
Orthotopic liver transplantation has been proposed as the 
only definitive curative option for the symptomatic liver 
involvement in HHT.
18 
In conclusion, the diagnosis of HCC in the liver involved 
by HHT can be difficult due to its vascular malformation and 
regenerative nodular hyperplasia. TACE is ineffective in 
patients with HCC associated with HHT, therefore liver 
transplantation should be considered as the first-line treatment 
modality. We report here a case of HHT, presenting with 
HCC which developed in the background of multiple 
intrahepatic AVMs.
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